LAUSR

ENIUS. European Network of multidisciplinary research to Improve the Urinary Stents. COSTS Actions. CA16217. European Cooperation in Science & Technology Springer-Verlag GmbH Germany, part of Springer Nature 2020 Selected Abstracts from the ‘‘Advances in Urinary Stents. Biomaterials, Coatings and Drug Eluting Stents’’. Training School Meeting. Name of Meeting Organizer. European Network of multidisciplinary research to Improve the Urinary Stents (ENIUS). COSTS Actions. CA16217. European Cooperation in Science & Technology. University of Lublin (Poland), 26th–27th September, 2019. Selected Abstracts from the ‘‘Advances in Urinary Stents technology’’. Workshop. Name of Meeting Organizer. European Network of multidisciplinary research to Improve the Urinary Stents (ENIUS). COSTS Actions. CA16217. European Cooperation in Science & Technology. Serbian Academy of sciences and Arts, Belgrade (Serbia), 7th March, 2020. Sponsorship: Publication of this supplement was funded by ENIUS COST Action. All content was reviewed and approved by the Society Committee, which held full responsibility for the abstract selections. Dr. Federico Soria (Spain). ENIUS network (2017–2021) bring together European translational scientists, urologists, bioengineers, chemists, to foster the dialogue and exchange expertise and to contribute to enhancing the urinary stents and reduce the morbidity of stented patients. Currently, ENIUS is composed of 262 researchers from 36 different countries. It is the largest research network in urinary stents in the world. ( http://www.enius.org). COST provides networking opportunities for researchers and innovators in order to strengthen Europe’s capacity to address scientific, technological and societal challenges. The three strategic priorities: – Promoting and spreading excellence. – Fostering interdisciplinary research for breakthrough science. – Empowering and retaining young researchers and innovators. 1. Advances in Urinary Stents. Biomaterials, Coatings and Drug Eluting Stents (DES). Training School. 26th–27th September, 2019. Lublin (Poland). 2. Advances in Urinary Stents technology. Workshop. 7th March, 2020. Belgrade (Serbia). 1. Preliminary assessment of the MMC BraidStent : a mitomycin C-eluting biodegradable ureteral stent Julia E. de la Cruz, Maria Soto, Alberto Budı́a, Juan Pablo Caballero, Francisco Sánchez-Margallo, Federico Soria Jesús Usón Minimally Invasive Surgery Centre, JUMISC, Caceres, Spain; Urology Department, La Fe University Hospital, Valencia, Spain; Urology Department, General University Hospital, Alicante, Spain The objective of this line of research is the development of a biodegradable drug-eluting ureteral stent, for the topical adjuvant treatment of upper urinary tract urothelial carcinoma: MMC BraidStent . BraidStent is a biodegradable intra-ureteral stent, whose safety and efficacy in vitro and in vivo has been proved by our research group in previous studies. The efforts of our research nowadays are focused on the development of the polymer that is able to coat the stent and to carry and release Mitomycin C (MMC), at appropriate doses and timing. We have tested in vitro a polymeric matrix of natural origin. The first evaluation included the study of the coating dyed with Sulforhodamine B (SrB), to assess the feasibility of attachment to the biodegradable materials of the BraidStent . Besides, three different coating techniques for controlled drug 123 Urolithiasis (2020) 48:553–559 https://doi.org/10.1007/s00240-020-01218-2